# A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

> **NCT05001282** · PHASE1,PHASE2 · TERMINATED · sponsor: **Elucida Oncology** · enrollment: 79 (actual)

## Conditions studied

- Ovarian Cancer
- Ovarian Neoplasms
- Ovarian Carcinoma
- Endometrial Cancer
- Ovary Cancer
- Ovary Neoplasm
- Ovary Disease
- Ovary Metastasis
- Ovarian Diseases
- Ovarian Cancer Stage
- Ovarian Epithelial Cancer
- Ovarian Adenocarcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Neoplasm Epithelial
- Ovarian Cancer Recurrent
- Endometrial Diseases
- Endometrial Adenocarcinoma
- Endometrial Carcinosarcoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrioid Adenocarcinoma
- Endometrial Neoplasms
- Endometrial Cancer Recurrent
- Endometrioid Tumor
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** ELU001

## Key facts

- **NCT ID:** NCT05001282
- **Lead sponsor:** Elucida Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-13
- **Primary completion:** 2024-06-07
- **Final completion:** 2024-06-07
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** Lack of Funding - no safety issue with Drug; Company Permanently Closed
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05001282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05001282, "A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05001282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*